Description
Lumos Diagnostics -ViraDx™ SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.
Point of Care (POC) EUA 25 Tests/Box
Buy with confidence with greater than 12 month expiration dates.
Click Here for Buy 5 Boxes Get One Box Free Promo for a Limited Time
Benefits of using ViraDx
- Efficient: 1 sample – 3 results to aid in a differential diagnosis at the point of care
- Rapid: actionable results in 15 minutes to help improve patient management decisions during the patient visit
- Instrument-free: user-friendly test procedure for non-lab settings
- Accurate
- COVID-19: Sensitivity 93.4%; Specificity 100%
- Flu A: Sensitivity 91.4%; Specificity 95.7%
- Flu B: Sensitivity 87.6%; Specificity 95.9%
| Time to results | 15 minutes |
| Sample type | Anterior nasal or nasopharyngeal swab specimen |
| Interpretation | Visually read (no instrument required) |
| Method | Lateral flow |
| Storage conditions | 2 to 30°C (35 to 86°) |
